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Essential oils (EOs) have long been known to provide healing effects. This study’s
aim was to assess the inhibitory effects on cystic ﬁbrosis (CF) pathogens of EOs
commonly used in aroma and massage therapies for respiratory conditions. Disk
diffusion (DD) and vapor exposure assays were employed, and EO zones of growth
inhibition (ZOIs) recorded for agar-plated clinical isolates and laboratory strains
of CF pathogens, including P. aeruginosa (PA), S. aureus (SA), and C. albicans
(CA). A variety of common EOs inhibited mucoid & non-mucoid PA, SA, CA
and other isolates. Sensitivities varied among isolates of a given species. Mixed
cultures from sputa were generally more susceptible than those of throat origin.
EOs with signiﬁcant amounts of volatile components eugenol, eucalyptol, carvacrol,
thymol, or cinnamaldehyde provided the widest range and most signiﬁcant antibiotic
activity, i.e. allspice, basil, bay, bay laurel, cassia, cinnamon, clove, oregano, and
thyme white. MRSA were inhibited well in both diffusion and vapor assays by
cassia, cinnamon bark, oregano, and thyme white oils (>25mm ZOIs). Of other
tested common oils used in rubs or inhalants, eucalyptus and wintergreen were
most inhibitory. Oregano, thyme, and cassia oil were the most widely effective
against mixed cultures obtained from polymicrobial CF specimens, (i.e. DD ZOIs
ranges: 20−34, 22−31, 13−20mm respectively). In conclusion, numerous essential
oils were effective inhibitors of CF pathogens in vitro, suggesting that, if proven
safe, such volatile oils (or modiﬁed components) may be useful as inhaled adjuvants
to standard antibiotic therapies for chronic and/or complex cystic ﬁbrosis infections.
77 Risk factor of multi-drug resistant Pseudomonas aeruginosa
(MDR-PA) emergence in cystic ﬁbrosis patients
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Introduction: Infection with MDR-PA causes much concern among caregivers. MDR-
PA is associated with a more rapid decline of FEV1 and more frequent antibiotic
courses. The aim of this study was to identify risk factors for the emergence of MDR-
PA deﬁned by resistance to at least two of the following classes: b-lactamine, aminoside
and quinolone.
Methods: Retrospective study including all the patients of our Cystic Fibrosis Depart-
ment between 2008 and 2011 with at least one sputum culture showing PA. To compare
patients with and without MDR-PA, clinical parameters and antibiotic courses before
the onset of MDR-PA were analysed.
Results: Among 38 patients included, 14 had an infection with MDR-PA. The risk or
protective factors for the emergence of MDR-PA determined in univariate analysis are
detailed in Table 1 and Table 2 respectively.
Conclusion: MDR-PA emergence is associated with some patient’s characteristics and
more antibiotic use but also with the modality of antibiotic courses.
Table 1
Odds ratio [95%CI] p-value
Having a family member presenting cystic ﬁbrosis 31.9 [6.9–147.3] <0.001
Having a PA colonisation 7.1 [1.3–38.8] 0.007
Having a mucoid PA 5 [1.12–22.4] 0.029
Presenting a nasal polyposis 7.1 [1.6–31.3] 0.007
Receiving more frequently an antibiotic active against PA 12 [2.1–67.1] 0.002
Receiving more frequently an aminoside 7.1 [1.3–38.8] 0.015
Having a neutrophil range above median at exacerbation 8.6 [1.7–42.2] 0.02
Table 2
Odds ratio [95%CI] p-value
Receiving more frequently antibiotics by oral route 0.17 [0.04–0.71] 0.011
Receiving more frequently than median a mono antibiotherapy 0.15 [0.03–0.68] 0.01
Having a continous administration of Ceftazidim 0.17 [0.03–1.018] 0.045
Having a dosage of aminoside pic in sera more than median 0.06 [0.01–0.36] 0.001
Having a dosage of aminoside valley in sera more than median 0.09 [0.02–0.47] 0.003
78 Development of resistance in CF pathogens exposed to
fosfomycin:tobramycin (4:1 w/w) under aerobic and anaerobic
conditions
G. McCaughey1, J.S. Elborn1, M. McKevitt2, M. Tunney1, CF and Airways
Microbiology Research Group. 1CF and Airways Microbiology Research Group,
Queen’s University Belfast, Belfast, United Kingdom; 2Gilead Sciences Inc, Seattle,
United States
Background: Fosfomycin/tobramycin for inhalation (FTI) is being investigated as
a treatment option for bacterial respiratory infection.
Aims: To investigate development of resistance when MRSA and Pseudomonas
aeruginosa (PA) isolates from CF patients were exposed to fosfomycin, tobramycin
and fosfomycin/tobramycin in a 4:1 (w/w) ratio (F:T) under aerobic and anaerobic
conditions.
Methods: Late log phase cultures of MRSA (n = 5) and PA (n = 5) isolates were
exposed to 2, 4 and 8 X aerobic and anaerobic MICs of fosfomycin, tobramycin
and F:T. Spontaneous mutation frequency was calculated by dividing the number
of resistant colonies after 48h by the original inoculum. Development of resistance
after serial exposure was investigated by passaging PA (n = 3) and MRSA (n = 3) in
sub-MIC concentrations of fosfomycin, tobramycin and F:T for 12 passages, with
MICs determined every 3 passages.
Results: MRSA and PA isolates had lower mutation frequencies when exposed to
F:T compared to fosfomycin and tobramycin alone under both conditions. In multi-
step resistance studies, there was no increase in F:T MIC when PA and MRSA
isolates were exposed to low concentrations of F:T for 12 passages. In contrast
PA (n = 2) and MRSA (n = 3) isolates developed resistance to fosfomycin under
aerobic conditions with one PA isolate also developing resistance under anaerobic
conditions. One MRSA and 1 PA isolate developed resistance to tobramycin under
aerobic conditions, while two MRSA isolates developed resistance under anaerobic
conditions.
Conclusion: This study demonstrates that CF isolates are less likely to develop
resistance when exposed to F:T compared to fosfomycin or tobramycin alone.
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Background: Potentially pathogenic Prevotella spp. have been detected in sputum
samples from CF patients. Standard treatment does not target such anaerobes as
their role in disease progression is unknown.
Aims:
i. To determine in vitro antimicrobial susceptibility of CF and non-CF Prevotella
isolates to antibiotics used in the treatment of both CF pulmonary infection and
anaerobic infections and
ii. identify genes associated with resistance (cfxA/cfxA2, nim and ermF).
Methods: Susceptibility of Prevotella isolates from CF (n = 35) and non-CF (n = 49)
patients, to amoxicillin, ceftazidime, clindamycin, co-amoxiclav, meropenem,
metronidazole, piperacillin/tazobactam (pip/taz) and tobramycin was determined
by E-test®. Each isolate was screened for cfxA/cfxA2, nim and ermF genes using
PCR assays.
Results: Amoxicillin (55%), ceftazidime (29%) and metronidazole (4%) resistance
was similar between CF and non-CF isolates. Clindamycin (CF, 58%; non-CF, 11%)
and co-amoxiclav (CF, 26%; non-CF, 9%) resistance was higher among CF isolates.
All isolates were sensitive to meropenem and pip/taz but resistant to tobramycin.
Thirty of 45 (67%) isolates had reduced susceptibility to amoxicillin and were
positive for cfxA/cfxA2. Eleven of 31 (35%) CF isolates were positive for ermF
compared to 9/44 (20%) non-CF isolates. Three of 72 (4%) isolates were positive
for nim but sensitive to metronidazole.
Conclusions: Amoxicillin resistance is common and can be linked with cfxA/cfxA2.
Resistance to clindamycin (linked with ermF) and co-amoxiclav was more common
among Prevotella isolates from CF patients. Metronidazole, meropenem and pip/taz
resistance was not common.
